Literature DB >> 16421644

Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection.

Yoshihide Asano1, Maiko Sarukawa, Takeo Idezuki, Syoichiro Harada, Kenzo Kaji, Ichiro Nakasu, Atsuyuki Igarashi.   

Abstract

Antiphospholipid antibodies (aPL) have been reported to occur in several conditions other than antiphospholipid syndrome, including infections. We herein report the case of a 21-year-old Japanese woman with Parvovirus B19 infection, who developed multiple pulmonary emboli associated with aPL, a lupus anticoagulant and IgM anticardiolipin antibody. Eight weeks later, antiphospholipid antibodies spontaneously disappeared and normal pulmonary flow was observed. Considering the high prevalence of Parvovirus B19 infection, we should be aware of thrombosis associated with transient aPL antibodies in this infectious disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421644     DOI: 10.1007/s10067-005-0032-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

1.  Transient anticardiolipin antibody syndrome in a patient with parvovirus B19 infection.

Authors:  T Reitblat; T Drogenikov; I Sigalov; S Oren; D London
Journal:  Am J Med       Date:  2000-10-15       Impact factor: 4.965

2.  Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus.

Authors:  E Oger; C Lernyer; M Dueymes; E Le Moigne; L Bressolette; M Escoffre; P Youinou; D Mottier
Journal:  Lupus       Date:  1997       Impact factor: 2.911

3.  Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.

Authors:  J Ordi-Ros; J Villarreal; F Monegal; S Sauleda; I Esteban; M Vilardell
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

4.  Is there a phospholipid specificity of lupus anticoagulants (LAC) in patients with autoimmune and drug induced LAC?

Authors:  E V Hess
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

5.  High prevalence of anticardiolipin antibodies in hepatitis C virus infection: lack of effects on thrombocytopenia and thrombotic complications.

Authors:  M Harada; Y Fujisawa; S Sakisaka; T Kawaguchi; E Taniguchi; M Sakamoto; S Sumie; K Sasatomi; H Koga; T Torimura; T Ueno; K Gondo; H Yoshida; K Tanikawa; M Sata
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

6.  Prevalence and clinical significance of anticardiolipin antibodies in pregnancies complicated by parvovirus B19 infection.

Authors:  E Gratacós; P J Torres; J Vidal; J Font; E Antolin; V Cararach; A Fortuny
Journal:  Prenat Diagn       Date:  1995-12       Impact factor: 3.050

7.  Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.

Authors:  J Cabiedes; A R Cabral; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1995-10       Impact factor: 4.666

Review 8.  Viral infections and antiphospholipid antibodies.

Authors:  Imad W Uthman; Azzudin E Gharavi
Journal:  Semin Arthritis Rheum       Date:  2002-02       Impact factor: 5.532

Review 9.  Parvovirus B19 infection and autoimmune disease.

Authors:  Hartwig W Lehmann; Philipp von Landenberg; Susanne Modrow
Journal:  Autoimmun Rev       Date:  2003-06       Impact factor: 9.754

10.  Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies.

Authors:  M Galli; P Comfurius; T Barbui; R F Zwaal; E M Bevers
Journal:  Thromb Haemost       Date:  1992-09-07       Impact factor: 5.249

  10 in total
  6 in total

Review 1.  Catastrophic APS in the context of other thrombotic microangiopathies.

Authors:  Ignasi Rodríguez-Pintó; Gerard Espinosa; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 2.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

Review 3.  Antiphospholipid antibodies in response to infection.

Authors:  Tadej Avcin; Natasa Toplak
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

Review 4.  Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.

Authors:  Anush Martirosyan; Rustam Aminov; Gayane Manukyan
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 5.  Review: Viral infections and mechanisms of thrombosis and bleeding.

Authors:  M Goeijenbier; M van Wissen; C van de Weg; E Jong; V E A Gerdes; J C M Meijers; D P M Brandjes; E C M van Gorp
Journal:  J Med Virol       Date:  2012-10       Impact factor: 2.327

6.  Splenic infarcts as a rare manifestation of parvovirus B19 infection.

Authors:  Georgios Kranidiotis; Efrosini Efstratiadis; Georgios Kapsalakis; Georgios Loizos; Apostolos Bilis; Andreas Melidonis
Journal:  IDCases       Date:  2016-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.